EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus

Bin Guo, Shaliheng Yerken, Chu Luo, Zhicheng Liu, Shenjie Xie, Yang Wu, Yongyi Zeng, Hui Zhang, Changzhen Shang iD, Guandou Yuan, Enyu Liu, Fan Zhang und 1 weitere

BJS Open · 05.03.2026 · 10 (2)

DOI: 10.1093/bjsopen/zrag007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJS Open, online erschienen am 23.03.2026. Verfasst von Bin Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Hepatectomy, Immune Checkpoint Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tongji Hospital Clinical Research Fund, National Natural Science Foundation of China, Science and Technology Innovation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Portal vein tumour thrombus (PVTT) significantly worsens the prognosis of hepatocellular carcinoma. Although combination therapy involving immune checkpoint inhibitors, anti-angiogenics, and locoregional treatment has shown promising anti-tumour activity, the comparative effectiveness of liver resection versus transarterial chemoembolization within such regimens remains unclear.

Methods

This multicentre, retrospective study enrolled patients with hepatocellular carcinoma and PVTT who received either liver resection or transarterial chemoembolization, each combined with PD-1 inhibitors and lenvatinib (LRPL and TPL, respectively), between 2019 and 2023. Survival outcomes were compared using the Kaplan–Meier method. Propensity score matching was applied to balance baseline characteristics and reduce potential confounding between the two groups.

Results

A total of 430 patients were included, and 155 patients remained in each cohort after 1:1 propensity score matching. The LRPL cohort showed significantly longer overall survival than the TPL cohort, with a median(interquartile range) overall survival of 34.0 (30.0–45.9) months versus 22.9 (19.3–31.2) months (hazard ratio 0.71, 95% confidence interval 0.53 to 0.95; P < 0.001). Subgroup analysis revealed that the overall survival benefit of LRPL was primarily observed in patients with PVTT limited to secondary branches (hazard ratio 0.36, 0.21 to 0.64; P < 0.001). In contrast, no significant difference was found when PVTT involved the primary branches or main trunk (hazard ratio 0.91, 0.68 to 1.41; P = 0.240).

Conclusions

The LRPL strategy was associated with superior survival compared with TPL, especially in patients with secondary branch PVTT, indicating its potential as the preferred therapeutic option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticHepatectomyImmune Checkpoint InhibitorsLiver NeoplasmsPhenylurea CompoundsQuinolinesVenous ThrombosisAgedFemaleHumansMaleMiddle AgedCombined Modality TherapyPortal VeinPropensity ScoreRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

conversion resectionimmune checkpoint inhibitorsimmunotherapylocoregional therapytargeted therapy

Substanzen

Immune Checkpoint InhibitorslenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Hepatobiliary and Pancreatic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
  • Organ Transplant Department, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

ORCID-Profile: Changzhen Shang, Wanguang Zhang

Förderung

  • Tongji Hospital Clinical Research Fund
  • National Natural Science Foundation of China
  • Science and Technology Innovation of Hubei Province

Zitieren

APA

Guo, B., Yerken, S., Luo, C., Liu, Z., Xie, S., Wu, Y., Zeng, Y., Zhang, H., Shang, C., Yuan, G., Liu, E., Zhang, F., & Zhang, W. (2026). Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus. BJS Open, 10(2). https://doi.org/10.1093/bjsopen/zrag007

Vancouver

Guo B, Yerken S, Luo C, Liu Z, Xie S, Wu Y, et al. Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus. BJS Open. 2026;10(2). doi:10.1093/bjsopen/zrag007

BibTeX
@article{Guo2026,
  author = {Guo, Bin and Yerken, Shaliheng and Luo, Chu and Liu, Zhicheng and Xie, Shenjie and Wu, Yang and Zeng, Yongyi and Zhang, Hui and Shang, Changzhen and Yuan, Guandou and Liu, Enyu and Zhang, Fan and Zhang, Wanguang},
  title = {Liver resection versus transarterial chemoembolization plus PD-1 inhibitors and lenvatinib for hepatocellular carcinoma with portal vein tumour thrombus},
  journal = {BJS Open},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.1093/bjsopen/zrag007}
}
Kostenlos starten →